Locations:
SearchCleveland Clinic oncologist reviews new agents
Several new agents are showing promising results in treating non Hodgkin lymphomas (NHL). They include ibrutinib, venetoclax, idelalisib, chimeric antigen receptor (CAR)–modified T-cell therapy and obinutuzumab.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In this interview with OncLive.com, medical oncologist Mitchell Smith, MD, of Cleveland Clinic Cancer Center’s Department of Hematology and Medical Oncology discusses these recent NHL advances, some of which have “game-changing” potential.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients